Methods and materials for assessing allelic imbalance
US-9279156-B2 · Mar 8, 2016 · US
Cancer diagnosis, treatment selection and treatment
US10308986B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10308986-B2 |
| Application number | US-201414774772-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2014 |
| Priority date | Mar 14, 2013 |
| Publication date | Jun 4, 2019 |
| Grant date | Jun 4, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating cancer having increased expression of BLM and FANCI of at least two-fold compared to BRCA1 expression in a human subject in need thereof, said method comprising the step of administering a platinum-comprising cancer chemotherapy to the human subject. 2. A method of treating cancer having cancer cells with a chromosome 15q26 copy number gain compared to the cancer cells' chromosome 15centromere copy number in a human subject in need thereof, said method comprising the step of administering a platinum-comprising cancer chemotherapy to the human subject. 3. The method of claim 2 , wherein the cancer is selected from breast cancer, ovarian cancer and lung cancer. 4. The method of claim 2 , wherein the subject's cancer is known to not express a detectable quantity of ER, PgR, and HER2 receptor.
Assignees
Inventors
Classifications
of the breast · CPC title
Expression markers · CPC title
Polymorphic or mutational markers · CPC title
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10308986B2 cover?
- The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell…
- Who is the assignee on this patent?
- Childrens Medical Center, Brigham & Womens Hospital Inc, Dana Farber Cancer Inst Inc, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).